Skip to main content
70°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by UroGen Pharma Ltd.
< Previous
1
2
3
Next >
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces $120 Million Private Placement of Ordinary Shares
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
July 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
July 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
July 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
June 20, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
June 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 11, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 04, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
May 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
April 30, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
April 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
March 16, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
March 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 15, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
January 11, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 19, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
December 02, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.